Bestaande gebruiker? Log in
Abonneren
Home
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Analisten vandaag
Meest aanbevolen aandelen
Minst aanbevolen aandelen
Aandelen met grootste potentieel
Insider trading
Insiders vandaag
Meest gekochte aandelen
Meest verkochte aandelen
Mijn Trivano
Mijn Trivano
Mijn selecties
Mijn nieuwsbrieven
Abonneren
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Insider trading
Mijn Trivano
Registreren / inloggen
Beurs vandaag
Amerika
Intensity Therapeutics Inc
Nieuws
Intensity Therapeutics Inc
INTS
NAS
: INTS
| ISIN: US45828J1034
17/05/2024
4,890 USD
(-4,12%)
(-4,12%)
17/05/2024
Aandeel volgen
Aandeel gevolgd
Samenvatting
Nieuws
Insiders
Technische analyse
TA
Toon enkel gratis nieuws
15 mei 2024 ·
Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors
· Persbericht
10 mei 2024 ·
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate
· Persbericht
9 mei 2024 ·
Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
· Persbericht
2 april 2024 ·
Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024
· Persbericht
14 maart 2024 ·
Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
· Persbericht
14 maart 2024 ·
Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024
· Persbericht
21 februari 2024 ·
Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference
· Persbericht
3 januari 2024 ·
Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program
· Persbericht
12 december 2023 ·
Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer
· Persbericht
8 december 2023 ·
Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS
· Persbericht
1 december 2023 ·
Intensity Therapeutics Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium
· Persbericht
2 november 2023 ·
Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023
· Persbericht
7 september 2023 ·
Intensity Therapeutics Receives Orphan Drug Designation for the three key ingredients in INT230-6 for the Treatment of Soft Tissue Sarcoma
· Persbericht
5 september 2023 ·
Intensity Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
· Persbericht
14 augustus 2023 ·
Intensity Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update
· Persbericht
7 augustus 2023 ·
Intensity Therapeutics to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update
· Persbericht
Aandeel volgen
Aandeel gevolgd
Mijn selecties
Voorbeeldselectie
Je selectie is nog leeg.
Voeg nu effecten toe